Moxifloxacin Hydrochloride (CAS No.: 186826-86-8) - Broad-Spectrum Quinolone Antibacterial API
As a professional supplier of pharmaceutical-grade antibacterial active pharmaceutical ingredients (APIs), we provide Moxifloxacin Hydrochloride that strictly complies with global pharmacopoeia standards (USP, EP, CP). A fourth-generation fluoroquinolone antibacterial agent, it exhibits broad-spectrum antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, anaerobes, and atypical pathogens-making it a core medication for treating infections caused by susceptible bacteria in adults.
Product Basic Information
| Item | Details |
|---|---|
| Product Name | Moxifloxacin Hydrochloride |
| CAS No. | 186826-86-8 |
| Synonyms | Moxifloxacin HCl; 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid hydrochloride |
| Molecular Formula | C₂₁H₂₅ClFN₃O₄ |
| Molecular Weight | 437.89 |
| Appearance | Light yellow to yellow crystalline powder |
| Specification | Pharmaceutical grade; Purity ≥99.0% (HPLC); Moisture ≤5%; Heavy metals ≤20ppm |
| Melting Point | 324-325°C |
| Boiling Point | 636°C (at 760 mmHg) |
| Specific Optical Rotation | [α]²⁵D -256° (c=0.5, H₂O) |
| Storage Conditions | Store sealed at 2-8°C, away from heat sources, open flames, and organic chemicals |
| Solubility | Slightly soluble in water (soluble up to 5mg/mL when heated, forming a clear solution); soluble in dimethyl sulfoxide (DMSO) |
Core Functions & Applications
Moxifloxacin Hydrochloride exerts its antibacterial effect by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV-key enzymes involved in bacterial DNA replication, repair, and transcription. Its bactericidal activity is concentration-dependent, and the minimum bactericidal concentration (MBC) is essentially consistent with the minimum inhibitory concentration (MIC). This drug is mainly used to treat various infections caused by susceptible bacteria in adults (≥18 years old), with specific applications as follows:
1. Systemic Infection Treatment (Oral/Injection)
Respiratory Tract Infections: Serves as a first-line treatment for community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), and acute bacterial sinusitis (ABS). It demonstrates significant efficacy against infections caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, etc.
Skin and Soft Tissue Infections: Used to treat moderate-to-severe skin and soft tissue infections caused by susceptible bacteria such as Staphylococcus aureus and streptococci, including cellulitis and impetigo.
Other Infections: Also applicable for the treatment of bacterial conjunctivitis, endocarditis, and tuberculosis (as part of combination therapy in some cases).
Dosage Forms: Oral tablets (routine dosage adjusted based on infection type) and injectable formulations (for patients unable to take oral medications or with severe conditions, administered via intravenous infusion).
2. Local Infection Treatment (Ophthalmic Formulations)
Formulated into eye drops for the treatment of bacterial conjunctivitis caused by susceptible bacteria. Local administration delivers the drug directly to the infection site, minimizing systemic adverse reactions.
Quality & Safety Assurance
As a prescription drug, Moxifloxacin Hydrochloride requires strict quality control and standardized use:
Raw Materials & Production: Synthesized using high-purity intermediates. The production process is carried out in GMP-certified workshops, with strict control over reaction conditions, purification processes (e.g., column chromatography), and crystallization procedures to ensure product purity and stability. Each batch of products undergoes comprehensive testing, including HPLC purity analysis (single impurity content complies with pharmacopoeia standards), heavy metal detection, and moisture determination, to ensure medication safety.
Safety Precautions:
Photosensitivity Risk: Prolonged and excessive exposure to sunlight or ultraviolet (UV) radiation during treatment may cause moderate-to-severe photosensitivity reactions, such as skin burning, blistering, and erythema. Sun protection measures (e.g., wearing sunglasses, applying sunscreen) should be taken during medication. Discontinue use immediately and seek medical attention if reactions occur.
Antimicrobial Resistance: Although effective against most drug-resistant strains, it must be used strictly as prescribed by a doctor to avoid abuse and the development of enhanced drug resistance.
Contraindications & Precautions: Contraindicated in patients allergic to fluoroquinolone drugs; used with caution in patients with a history of epilepsy or QT interval prolongation; not recommended for pregnant women, lactating women, and children.
Cooperation & Contact
We supply pharmaceutical-grade Moxifloxacin Hydrochloride API, which meets the production needs of various formulations such as oral, injectable, and topical medications. We offer flexible supply services ranging from gram-level R&D samples to kilogram-level bulk orders. If you are a pharmaceutical enterprise, R&D institution, or formulation manufacturer, please contact us for detailed specifications, pricing, bulk discounts, or technical support (e.g., formulation compatibility, stability guidance):
Contact Information:
Email: sales@huarongpharma.com
Phone/WhatsApp: +86 13751168070
We adhere to the principle of "quality first, compliant operation" and look forward to establishing long-term, mutually beneficial cooperative relationships with global partners!
Hot Tags: Moxifloxacin Hydrochloride, 186826-86-8, Pharmaceutical Grade Moxifloxacin Hydrochloride, Broad-Spectrum Antibacterial Drug, Fluoroquinolone API, Respiratory Tract Infection Treatment Drug
Hot Tags: Moxifloxacin Hydrochloride API CAS#186826-86-8, China Moxifloxacin Hydrochloride API CAS#186826-86-8 manufacturers, suppliers, CAS 19524 06 2, , , 1R 2R 2 Amino 1 4 nitrophenyl propane 1 3 diol
